Regorafenib (BAY 73-4506) , ≥99% , 755037-03-7
CAS NO.：755037-03-7
Empirical Formula: C21H15ClF4N4O3
Molecular Weight: 482.82
MDL number: MFCD16038047
EINECS: 815-051-1
| Pack Size | Price | Stock | Quantity |
| 5MG | RMB95.20 | In Stock |
|
| 10mg | RMB200.80 | In Stock |
|
| 25MG | RMB266.40 | In Stock |
|
| 100MG | RMB851.20 | In Stock |
|
| 500mg | RMB3139.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 206.0 to 210.0 °C |
| Boiling point: | 513.4±50.0 °C(Predicted) |
| Density | 1.491±0.06 g/cm3(Predicted) |
| storage temp. | Refrigerator |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 12.04±0.70(Predicted) |
| form | White powder. |
| color | Pale Pink to Light Pink |
| CAS DataBase Reference | 755037-03-7 |
Description and Uses
Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity. It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectivey) as well as other kinases. In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models. It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.
It inhibits PDGFR tyrosine kinase with IC50=83nM. It is useful for the treatment of inflammation and as an anti-proliferative agent.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| HS Code | 29242990 |
